Labcorp reports revenue gains for Q3

By LabPulse.com staff writers

October 29, 2021 -- Labcorp reported increased revenue but lower net earnings in its third quarter (end-September 30). The company has also revised upward its guidance for the rest of fiscal 2021.

For the period, Labcorp garnered $4.1 billion in revenue, up 4.3% from the $3.9 billion reported the same period last year. The company attributed the increase to organic growth, acquisitions, and foreign currency translation.

Net earnings dipped, however, to $587.3 million, down from $703.4 million in the third quarter of 2020. The decrease in earnings was primarily due to a reduction in COVID-19 tests and higher personnel costs, according to Labcorp.

As a result of its third-quarter performance, Labcorp adjusted its full year 2021 guidance. The company now expects 2021 revenue growth to range from 13.0% to 14.0%, up from previous guidance of 6.5% to 9%.

Labcorp, Pillar Biosciences team up for genomic testing
Labcorp and Pillar Biosciences have signed an agreement to offer genomic cancer testing based on Pillar's next-generation sequencing technology.
GeneCentric Therapeutics teams up with Labcorp
GeneCentric Therapeutics has formed a strategic partnership with Labcorp to develop and commercialize RNA-based gene signatures for oncology diagnostics.
Labcorp acquires women's digital health firm Ovia
Labcorp announced it has acquired digital health firm Ovia Health in a move the company said aims to improve patient experience and reduce healthcare...
Labcorp deploys new SARS-CoV-2 sequencing panel
Labcorp will start using Molecular Loop Biosciences' SARS-CoV-2 research sequencing panel to sequence thousands of complete coronavirus genomes each week...
OmniSeq, Labcorp launch new oncology test
OmniSeq and Labcorp have launched OmniSeq Insight, a new test based on next-generation sequencing that's intended to help improve oncology treatment and...

Copyright © 2021 LabPulse.com

Last Updated bc 11/2/2021 8:40:20 AM